465 related articles for article (PubMed ID: 36768666)
1. Pharmacological Utility of PPAR Modulation for Angiogenesis in Cardiovascular Disease.
Wagner N; Wagner KD
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768666
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Touyz RM; Schiffrin EL
Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
[TBL] [Abstract][Full Text] [Related]
3. [PPARs: physiological functions and pharmacological roles of agonists in human diseases. Note II].
Filip-Ciubotaru F; Manciuc C; Grigore C; Foia L
Rev Med Chir Soc Med Nat Iasi; 2012; 116(1):240-7. PubMed ID: 23077903
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels.
Aleshin S; Grabeklis S; Hanck T; Sergeeva M; Reiser G
Mol Pharmacol; 2009 Aug; 76(2):414-24. PubMed ID: 19483106
[TBL] [Abstract][Full Text] [Related]
5. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
[TBL] [Abstract][Full Text] [Related]
6. PPAR dual agonists: are they opening Pandora's Box?
Balakumar P; Rose M; Ganti SS; Krishan P; Singh M
Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
[TBL] [Abstract][Full Text] [Related]
7. The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges.
Cheang WS; Tian XY; Wong WT; Huang Y
Br J Pharmacol; 2015 Dec; 172(23):5512-22. PubMed ID: 25438608
[TBL] [Abstract][Full Text] [Related]
8. PPARs and Myocardial Infarction.
Wagner KD; Wagner N
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33322384
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review.
Grygiel-Górniak B
Nutr J; 2014 Feb; 13():17. PubMed ID: 24524207
[TBL] [Abstract][Full Text] [Related]
10. PPARs as therapeutic targets in cardiovascular disease.
van Bilsen M; van Nieuwenhoven FA
Expert Opin Ther Targets; 2010 Oct; 14(10):1029-45. PubMed ID: 20854178
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic roles of peroxisome proliferator-activated receptor agonists.
Staels B; Fruchart JC
Diabetes; 2005 Aug; 54(8):2460-70. PubMed ID: 16046315
[TBL] [Abstract][Full Text] [Related]
12. A PPARs cross-talk concertedly commits C6 glioma cells to oligodendrocytes and induces enzymes involved in myelin synthesis.
Leisewitz AV; Urrutia CR; Martinez GR; Loyola G; Bronfman M
J Cell Physiol; 2008 Nov; 217(2):367-76. PubMed ID: 18543250
[TBL] [Abstract][Full Text] [Related]
13. PPAR control of metabolism and cardiovascular functions.
Montaigne D; Butruille L; Staels B
Nat Rev Cardiol; 2021 Dec; 18(12):809-823. PubMed ID: 34127848
[TBL] [Abstract][Full Text] [Related]
14. Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease.
Robinson E; Grieve DJ
Pharmacol Ther; 2009 Jun; 122(3):246-63. PubMed ID: 19318113
[TBL] [Abstract][Full Text] [Related]
15. Inflammation, dyslipidaemia, diabetes and PPars: pharmacological interest of dual PPARalpha and PPARgamma agonists.
Gervois P; Fruchart JC; Staels B
Int J Clin Pract Suppl; 2004 Oct; (143):22-9. PubMed ID: 16035393
[TBL] [Abstract][Full Text] [Related]
16. PPAR ligands: are they potential agents for cardiovascular disorders?
Balakumar P; Rose M; Singh M
Pharmacology; 2007; 80(1):1-10. PubMed ID: 17496434
[TBL] [Abstract][Full Text] [Related]
17. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
Huang TH; Roufogalis BD
Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
[TBL] [Abstract][Full Text] [Related]
18. PPAR Ligands Containing Stilbene Scaffold.
Fantacuzzi M; De Filippis B; Amoroso R; Giampietro L
Mini Rev Med Chem; 2019; 19(19):1599-1610. PubMed ID: 31161987
[TBL] [Abstract][Full Text] [Related]
19. The Glitazars Paradox: Cardiotoxicity of the Metabolically Beneficial Dual PPARα and PPARγ Activation.
Kalliora C; Drosatos K
J Cardiovasc Pharmacol; 2020 Nov; 76(5):514-526. PubMed ID: 33165133
[TBL] [Abstract][Full Text] [Related]
20. The role of peroxisome proliferator-activated receptors in healthy and diseased eyes.
Escandon P; Vasini B; Whelchel AE; Nicholas SE; Matlock HG; Ma JX; Karamichos D
Exp Eye Res; 2021 Jul; 208():108617. PubMed ID: 34010603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
